|
|
Line 1: |
Line 1: |
| [[Image:1o99.gif|left|200px]] | | {{Seed}} |
| | [[Image:1o99.png|left|200px]] |
|
| |
|
| <!-- | | <!-- |
Line 9: |
Line 10: |
| {{STRUCTURE_1o99| PDB=1o99 | SCENE= }} | | {{STRUCTURE_1o99| PDB=1o99 | SCENE= }} |
|
| |
|
| '''CRYSTAL STRUCTURE OF THE S62A MUTANT OF PHOSPHOGLYCERATE MUTASE FROM BACILLUS STEAROTHERMOPHILUS COMPLEXED WITH 2-PHOSPHOGLYCERATE'''
| | ===CRYSTAL STRUCTURE OF THE S62A MUTANT OF PHOSPHOGLYCERATE MUTASE FROM BACILLUS STEAROTHERMOPHILUS COMPLEXED WITH 2-PHOSPHOGLYCERATE=== |
|
| |
|
|
| |
|
| ==Overview==
| | <!-- |
| Phosphoglycerate mutases catalyze the isomerization of 2 and 3-phosphoglycerates, and are essential for glucose metabolism in most organisms. Here, we further characterize the 2,3-bisphosphoglycerate-independent phosphoglycerate mutase (iPGM) from Bacillus stearothermophilus by determination of a high-resolution (1.4A) crystal structure of the wild-type enzyme and the crystal structure of its S62A mutant. The mutant structure surprisingly showed the replacement of one of the two catalytically essential manganese ions with a water molecule, offering an additional possible explanation for its lack of catalytic activity. Crystal structures invariably show substrate phosphoglycerate to be entirely buried in a deep cleft between the two iPGM domains. Flexibility analyses were therefore employed to reveal the likely route of substrate access to the catalytic site through an aperture created in the enzyme's surface during certain stages of the catalytic process. Several conserved residues lining this aperture may contribute to orientation of the substrate as it enters. Factors responsible for the retention of glycerate within the phosphoenzyme structure in the proposed mechanism are identified by molecular modeling of the glycerate complex of the phosphoenzyme. Taken together, these results allow for a better understanding of the mechanism of action of iPGMs. Many of the results are relevant to a series of evolutionarily related enzymes. These studies will facilitate the development of iPGM inhibitors which, due to the demonstrated importance of this enzyme in many bacteria, would be of great potential clinical significance.
| | The line below this paragraph, {{ABSTRACT_PUBMED_12729763}}, adds the Publication Abstract to the page |
| | (as it appears on PubMed at http://www.pubmed.gov), where 12729763 is the PubMed ID number. |
| | --> |
| | {{ABSTRACT_PUBMED_12729763}} |
|
| |
|
| ==About this Structure== | | ==About this Structure== |
Line 29: |
Line 33: |
| [[Category: Alpha/beta-type structure]] | | [[Category: Alpha/beta-type structure]] |
| [[Category: Isomerase]] | | [[Category: Isomerase]] |
| ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 03:32:53 2008'' | | |
| | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 21:38:50 2008'' |